The company, which raised $460 million in an IPO in July, has developed a pipeline of selective agents, two of which have advanced to Phase I clinical trials.
Two new studies show that patients with advanced HR-positive, HER2-negative breast cancer had higher survival when they received combination therapies.
A new study found that FOXA1 missense mutations were enriched in metastatic breast tumors and were associated with lower response to aromatase inhibitors.
The company will provide proprietary algorithms for analyzing omics and imaging data to define predictors of drug response and identify new biomarkers.
The Phase Ib/II trial will assess dosage and antitumor activity of MEN1611 plus Erbitux for patients with PIK3CA-mutated, RAS and RAF wildtype advanced colorectal cancer.
In ASCO studies, one PI3K inhibitor showed efficacy in PIK3CA-mutated breast cancer patients progressing on CDK4/6 inhibitors, while the other yielded less encouraging signals.
A study evaluated data from a Phase I/II trial of Piqray combined with an aromatase inhibitor to find mechanisms of resistance hindering clinical benefit from the therapy.
Researchers found that about 12 percent to 15 percent of breast cancer patients carry multiple mutations in the gene, 95 percent of which are double mutations.
